Trial · NCT04331132
Tolvaptan add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal Dysfunction
NCT04331132, Not applicable, Unknown, Gia Dinh People Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tolvaptan add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal Dysfunction. Trials, record NCT04331132. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04331132
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tolvaptan add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal Dysfunction
- NCT number
- NCT04331132
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 128 participants, estimated
- Lead sponsor
- Gia Dinh People Hospital
- Conditions
- Acute Heart Failure
- Interventions
- Tolvaptan 15 MG
- First posted
- 2020-04-02
- Last updated
- 2022-08-11
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cumulative urine volume output at 48h after randomization | Hour 48 | Urine volume in mL |
| Secondary | Cumulative dose of furosemide at 48h after randomization | Hour 48 | Furosemide dose in mg |
| Secondary | Symptom of dyspnea by 7-point Likert scale at 24h and 48h after randomization | Hour 24, Hour 48 | 3: markedly better, 2: moderately better, 1: minimally better, 0: no change, -1: minimally worse, -2: moderately worse, -3: markedly worse |
| Secondary | Changes in body weight at 24h and 48h after randomization | Hour 24, Hour 48 | weight in gram |
| Secondary | Incidence of clinically relevant worsening renal function at 24h and 48h after randomization | Hour 24, Hour 48 | An increase in serum creatinine ≥ 0.3 mg/dL within 48 hours accompanying doubling the dose of furosemide according to the diuretic treatment protocol |
| Secondary | Changes in serum electrolytes measured at 12h, 24h and 48h after randomization | Hour 12, Hour 24, Hour 48 | Changes in serum sodium (mmol/L), potassium (mmol/L), chloride (mmol/L) |
| Secondary | Changes in urine electrolyte excretion at 6h, 24h and 48h | Hour 6, Hour 24, Hour 48 | Increase in sodium (mmol/L), potassium (mmol/L) and chloride (mmol/L) excretion adjusted for urine creatinine (umol/L) |
| Secondary | Changes in NT-proBNP at 48h after randomization | Hour 0, Hour 48 | Changes in NT-proBNP (pg/mL) |
| Secondary | Changes in mitral e' on echocardiography | Hour 24, Hour 48 | Average of septal e' (cm/s) and lateral e' (cm/s) on tissue doppler imaging in apical 4-chamber view |
| Secondary | Changes in E/e' ratio on echocardiography | Hour 24, Hour 48 | The ratio between mitral E (cm/s) and average e' (cm/s) |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04331132
GET https://conductscience.org/api/trials/v1/NCT04331132/registered